Social network
Company section
Company section



Corporate governance

The Company’s corporate governance agenda is founded on France’s AFEP-MEDEF Code, which lays out inter alia the principles of effective governance and rules regarding executive pay, control and transparency.The combination of Sanofi Articles of Association and Board Charter define the framework within which Sanofi implements its principles of corporate governance.

Since January 1, 2007, the functions of Chairman and Chief Executive Officer have been separated.

The Board of Directors

The Company is managed by a Board of Directors composed of 16 members, two of whom are representing employees, 11 directors are independent. Is considered as independent, a Director who has no relation whatsoever with the company, its group or its management which may impede his freedom of decision. Members of our Board of Directors are appointed for a maximum term of four years; reappointment of Directors is on a rotation basis. No more than one third of the serving members of our Board of Directors may be aged more than 70.

Subject to the authority expressly granted by law to the shareholders’ meetings, the Board of Directors deals with and decides upon all issues relating to the proper management of the company and other matters concerning the board. It determines the general direction of the company’s activities and ensures the right measures are undertaken.

The Chairman organizes and supervises the Board’s work and reports on it to the Annual General Meeting. He ensures the smooth functioning of the corporate bodies he chairs (Board of Directors and the Annual General Meeting).

Serge Weinberg has been Chairman of the Board of Directors since May 17, 2010.

Serge Weinberg is the Chairman of the Board of Directors

Serge Weinberg is the Chairman of the Board of Directors


Board Diversity

Each year, the Board of Directors conducts a review to ensure that there is an appropriate balance in its composition and in the composition of its Committees. In particular, the Board seeks to ensure a more balanced representation of men and women and diversity of background and country of origin, since the business of the Company is both diversified and global. As of December 31, 2015, women made up almost 38% of Sanofi’s Board’s membership in accordance. After the 2016 Annual General Meeting they will make up 46% in accordance with the AFEP-MEDEF Code.

The Board investigates and evaluates potential candidates whenever individual directors are up for election. With its latest appointments, the Board has reinforced its scientific and pharmaceutical expertise. It prizes talented directors, who are independent-minded, competent, dedicated and committed. 


Specialist Committees

The committees are tasked with providing specialist input to assist the board in its decision-making process. Their members are chosen by the board from among its members, based on their experience.

There are four specialized committees: the Audit Committee, the Compensation Committee, the Appointments and Governance Committee and the Strategy Committee.


Corporate Management

The Chief Executive Officer directs the Company and represents it with respect to third parties within the limits of its corporate objectives.

He enjoys the broadest powers to act on behalf of the company in all circumstances, subject to the authority granted by law to the Board of Directors and to the Shareholders’ general meeting.

Olivier Brandicourt is Chief Executive officer

Olivier Brandicourt
is Chief Executive officer

Executive Committee

Olivier Brandicourt as CEO chairs the Executive committee. The Executive Committee meets twice a month and comprises permanent members.

Further information about Olivier Charmeil

Olivier Charmeil, Executive Vice President and General Manager, General Medicines and Emerging Markets

Further information about Jérôme Contamine

Jérôme Contamine, Executive Vice President, Chief Financial Officer

Further information about Karen Linehan

Karen Linehan, Executive Vice President, Legal Affairs and General Counsel

David Loew, Executive Vice President and General Manager of Sanofi Pasteur

David Loew, Executive Vice President and General Manager of Sanofi Pasteur

Further information about Philippe Luscan

Philippe Luscan, Executive Vice President, Global Industrial Affairs

Further information about Alan Main

Alan Main, Executive Vice President, Consumer Healthcare

Further information about Muzammil Mansuri

Muzammil Mansuri, Ph.D., Executive Vice President, Strategy & Business Development

Further information about Dr Ameet Nathwani

Ameet Nathwani, MD, Executive Vice President, Medical Affairs

Further information about Stefan Oelrich

Stefan Oelrich, Executive Vice President, Diabetes & Cardiovascular

Further information about Roberto Pucci

Roberto Pucci, Executive Vice President, Human Resources

Further information about Bill Sibold

Bill Sibold, Executive Vice President, Sanofi Genzyme

Further information about Kathleen Tregoning

Kathleen Tregoning, Executive Vice President, External Affairs

Further information about Elias Zerhouni

Elias Zerhouni, MD, President, Global Research & Development